US 12331328
CRISPR/Cas9-mediated exon-skipping approach for USH2A-associated usher syndrome
granted A61KA61K48/0016A61K9/0019
Quick answer
US patent 12331328 (CRISPR/Cas9-mediated exon-skipping approach for USH2A-associated usher syndrome) held by Editas Medicine, Inc. expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Editas Medicine, Inc.
- Grant date
- Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K48/0016, A61K9/0019